Citadel Advisors
TRIL

Citadel Advisors’s Trillium Therapeutics Inc. TRIL Stock Holding History

Citadel Advisors’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-798,500
Closed -$14M – 15482
2021
Q3 		$14M Sell
798,500
-3,368,259
-81% -$39.4M ﹤0.01% 2523
2021
Q2 		$40.4M Buy
4,166,759
+654,608
+19% +$6.16M 0.01% 1309
2021
Q1 		$37.7M Sell
3,512,151
-590,971
-14% -$7.31M 0.01% 1290
2020
Q4 		$60.4M Buy
4,103,122
+359,710
+10% +$5.19M 0.02% 824
2020
Q3 		$53.2M Buy
3,743,412
+520,948
+16% +$5.19M 0.02% 820
2020
Q2 		$26.1M Sell
3,222,464
-220,770
-6% -$1.37M 0.01% 1274
2020
Q1 		$13.9M Buy
+3,443,234
New +$13M 0.01% 1536
2019
Q4 		– Sell
-34,899
Closed -$11K – 10046
2019
Q3 		$11K Buy
+34,899
New +$11.8K ﹤0.01% 9037
2019
Q1 		– Sell
-23,229
Closed -$40K – 10124
2018
Q4 		$40K Buy
+23,229
New +$69.7K ﹤0.01% 8542
2018
Q1 		– Sell
-24,622
Closed -$180K – 8996
2017
Q4 		$180K Buy
+24,622
New +$204K ﹤0.01% 7185

Other funds holding TRIL

Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Citadel Advisors's TRIL Position: Q4 2021 in Review

Citadel Advisors sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 798,500 shares — an estimated $14M sold.

Citadel Advisors first reported a position in TRIL in Q4 2017 and held it in 10 quarters. The position peaked at $60.4M in Q4 2020. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

  • Citadel Advisors reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
  • Citadel Advisors sold 798,500 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $14M.
  • Citadel Advisors first reported a position in Trillium Therapeutics Inc. in Q4 2017 and held it in 10 quarters.
  • Citadel Advisors's Trillium Therapeutics Inc. position peaked at $60.4M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Citadel Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.